Our study unravels a new pathway, regulated by obesity, implicating PPAT in prostate cancer aggressiveness and suggests new strategies for treatment of advanced prostate cancer involving CCR3 antagonists, which are currently being developed for other diseases including asthma17. Here, CCR3 is linked to obesity due to melanocortin 4 receptor deficiency.